Abstract
N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Current Topics in Medicinal Chemistry
Title: Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity
Volume: 6 Issue: 7
Author(s): Wenyu Wen, Wenning Wang and Mingjie Zhang
Affiliation:
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Abstract: N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Export Options
About this article
Cite this article as:
Wen Wenyu, Wang Wenning and Zhang Mingjie, Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity, Current Topics in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/156802606776894474
DOI https://dx.doi.org/10.2174/156802606776894474 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry The Nitric Oxide View: Perspectives and Applications
Current Medicinal Chemistry The Effects of Age on Precision Pinch Force Control Across Five Days of Practice
Current Aging Science From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Change in INSR, APBA2 and IDE Gene Expressions in Brains of Alzheimer's Disease Patients
Current Alzheimer Research Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Current Medicinal Chemistry Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms
Central Nervous System Agents in Medicinal Chemistry Isomannide and Derivatives. Chemical and Pharmaceutical Applications
Mini-Reviews in Organic Chemistry Telomere Shortening Is a Sole Mechanism of Aging in Mammals
Current Aging Science Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
Current Pharmaceutical Design Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data
Current Vascular Pharmacology Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Insight into Diverse Activities and Targets of Flavonoids
Current Drug Targets Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Aging Liver: Can Exercise be a Better Way to Delay the Process than Nutritional and Pharmacological Intervention? Focus on Lipid Metabolism
Current Pharmaceutical Design Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design